Annual report pursuant to Section 13 and 15(d)

FDA Refund

v3.10.0.1
FDA Refund
12 Months Ended
Sep. 30, 2018
Receivables [Abstract]  
FDA REFUND

10. FDA REFUND

 

On August 29, 2018, the Company received notification from the Food and Drug Administration (“FDA”) that the Company was being refunded $818,343 of 2016 product and establishment fees because the fees paid by the Company exceeded the costs of the FDA’s review of the associated Suprenza applications. The Company recorded as other income in the statements of operations the $818,343 receivable from the FDA as of September 30, 2018. The Company received the refund in full on October 1, 2018.